Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Go 6983

Go 6983
Contact us for more batch information
Select Batch
Purity:99.04%
Resource Download

Go 6983

Catalog No. T6313Cas No. 133053-19-7
Go 6983 is a pan-PKC inhibitor targeting PKCα, PKCβ, PKCγ, PKCδ, and PKCζ, exhibiting IC50 values of 7 nM, 7 nM, 6 nM, 10 nM, and 60 nM, respectively.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$36In Stock
2 mg$50In Stock
5 mg$76In Stock
10 mg$128In Stock
25 mg$258In Stock
50 mg$408In Stock
100 mg$593In Stock
1 mL x 10 mM (in DMSO)$80In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Go 6983"

Product Introduction

Bioactivity
Description
Go 6983 is a pan-PKC inhibitor targeting PKCα, PKCβ, PKCγ, PKCδ, and PKCζ, exhibiting IC50 values of 7 nM, 7 nM, 6 nM, 10 nM, and 60 nM, respectively.
In vitro
A 22.0 μg intravenous (i.v.) dose of Go6983 significantly inhibits 51.2% of tumor metastasis in the B16BL6 lung tumor model in mice.
In vivo
Go 6983 is a subtype-specific PKC inhibitor that targets the ATP binding site. It inhibits ΔPfPKB activity with an IC50 of 1 μM. When 1 μM Go 6983 is used in conjunction with 390 nM Ro-31-8425, it slightly inhibits Angiotensin II-induced PLD2 activity in PGSMCs. Treatment with Go 6983 (5 μM) results in significantly fewer cycles in the next generation compared to control cultures, and this treatment leads to a nearly 60% reduction in new ring formation in cultures of the malaria parasite. At a concentration of 300 μM, Go6983 decreases PKCμ autophosphorylation by 20% in NIH3T3 cells transfected with PKCμ. In scenarios involving cardiac reperfusion, treatment with Go6983 (100 nM) alongside PMNs restores left ventricular developed pressure and the rate of left ventricular pressure development to 89% and 74% of baseline values, respectively, significantly higher than treatment with PMNs alone. Compared to cardiac ischemia-reperfusion (I/R) + PMN, 100 nM Go6983 significantly inhibits PMN adhesion to endothelial cells and myocardial infiltration and reduces superoxide release by PMNs by 90%. Go6983 reduces myocardial contractile dysfunction after I/R in the presence of PMNs, likely due to reduced superoxide production. It notably inhibits superoxide release from leukocytes in patients previously sensitized to tree pollen antigens. Furthermore, Go6983 inhibits Ca(2+) accumulation in human vascular tissue cells, indicating its mechanism for vascular relaxation properties.
Kinase Assay
Phosphorylation reactions are carried out in a total volume of 100 μL, containing buffer C (50 mM Tris-HCl, pH 7.5, 10 mM β-mercaptoethanol), 4 mM MgCl2, 10 μg PS, 100 nM TPA, 5 μL of a Sf158 cell extract as a source of recombinant PKCμ or of Sf9 cell extracts as a source of other recombinant PKC isoenzymes, 10 μg of syntide 2 as substrate, and 35 μM ATP containing 1 μCi [γ-32P]ATP. In some experiments, PS and TPA are omitted or various inhibitors at concentrations indicated in the text are added. After incubation for 10 min at 30°C, the reaction is terminated by transferring 50 μL of the assay mixture onto a 20 mm square piece of phosphocellulose paper, which is washed 3 times in deionized water and twice in acetone. The radioactivity on each paper is determined by liquid scintillation counting.
AliasGoe 6983
Chemical Properties
Molecular Weight442.51
FormulaC26H26N4O3
Cas No.133053-19-7
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 22.1 mg/mL (50 mM)
5% DMSO+95% Saline: 1.11 mg/mL (2.5 mM, precipitation)
Solution Preparation Table
DMSO/5% DMSO+95% Saline
1mg5mg10mg50mg
1 mM2.2598 mL11.2992 mL22.5984 mL112.9918 mL
DMSO
1mg5mg10mg50mg
5 mM0.4520 mL2.2598 mL4.5197 mL22.5984 mL
10 mM0.2260 mL1.1299 mL2.2598 mL11.2992 mL
20 mM0.1130 mL0.5650 mL1.1299 mL5.6496 mL
50 mM0.0452 mL0.2260 mL0.4520 mL2.2598 mL
100 mM0.0226 mL0.1130 mL0.2260 mL1.1299 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords